

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (1/98)

Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. **IAM 467 PA**

First Inventor or Application Identifier **Michael G. Hayek**

Title **LUTEIN-CONTAINING SUPPLEMENT AND PROCESS FOR ENHANCING IMMUNE RESPONSE IN ANIMALS**

Express Mail Label No. **EJ148049005US**

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

2. ☒ Specification [Total Pages **26**]
(preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **17**]

4. Oath or Declaration [Total Pages **2**]

- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
- i. ☐ DELETION OF INVENTOR(S).
Signed statement attached deleting
inventor(s) named in the prior application, see
37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a
copy of the oath or declaration is supplied under Box 4b, is
considered to be part of the disclosure of the accompanying
application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 C.F.R. §3.73(b) Statement ☒ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ *Small Entity Statement(s) ☐ Statement filed in prior application
(PTO/SB/09-12) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☒ Other: **Check \$916.00 (filing fee)**

* A new statement is required to be entitled to pay small entity fees, except
where one has been filed in a prior application and is being relied upon.

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No:

Prior application information: Examiner _____

Group / Art Unit: _____

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

or ☒ Correspondence address below

(Insert Customer No. or Attach bar code label here):

Name

Susan M. Luna

Killworth, Gottman, Hagan & Schaeff, L.L.P

Address

One Dayton Centre

One South Main Street, Suite 500

City

Dayton

State

OH

Zip Code

45402-2023

Country

United States

Telephone

937-223-2050

Fax

937-223-0724

Name (Print/Type)

Susan M. Luna

Registration No. (Attorney/Agent)

38,769

Signature

Susan M. Luna

Date

4/13/99

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

LUTEIN-CONTAINING SUPPLEMENT AND PROCESS FOR ENHANCING IMMUNE RESPONSE IN ANIMALS

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. provisional application Serial No. 60/081,968,
5 filed April 16, 1998.

BACKGROUND OF THE INVENTION

This invention relates to a pet food supplement and process for enhancing immune
response and improving the overall health of companion animals such as cats and dogs, and more
particularly, to a pet food supplement and process which includes beneficial amounts of lutein in
10 the animal's diet.

Carotenoids are naturally-occurring plant pigments which are absorbed in varying degrees
by different species. Common carotenoids include β -carotene, lycopene, astaxanthin, and
canthaxanthin. These carotenoids are known to play an important role in modulating the immune
system and enhancing the health of these species. For example, canthaxanthin has been found to
15 prevent chemical-induced carcinogenesis in mice while α -carotene has been found to inhibit
human neuroblastoma cell proliferation. Canthaxanthin has also been found to increase
lymphocyte proliferation in rats and enhance the production of tumor necrosis factor (TNF) by
macrophages in hamsters. Astaxanthin and β -carotene have been found to increase ex vivo
antibody response of mouse splenocytes to T-dependent antigens. However, the majority of
20 studies to date have focused on the effects of β -carotene.

Few studies have been conducted with regard to the physiologic function of lutein, a major
blood carotenoid in some species (human, chicken). In some recent studies, it has been found that
dietary lutein decreases mammary tumor incidence, tumor growth and has shortened tumor
latency in mice challenged with a transplantable murine mammary tumor cell line. Dietary lutein
25 was also found to enhance lymphocyte proliferation in mouse splenocytes. Splenocytes from mice
injected peritoneally with lutein, astaxanthin, and β -carotene have shown enhanced antibody

response to T-dependent antigens. Therefore, carotenoids including lutein possess immuno-modulatory activities and may be important in disease etiology.

Accordingly, there is still a need in the art for promoting a healthy immune system in companion animals such as dogs and cats.

SUMMARY OF THE INVENTION

The present invention meets that need by providing a process for feeding a companion animal such as a dog or cat a diet containing an effective amount of lutein to enhance immune response and improve the overall health of the animal. Preferably, the animal is fed a diet which includes from about 1 to about 50 mg/day of lutein (from about 2 to about 315 mg lutein/kg diet). Such a diet provides sufficient lutein to be absorbed by the animal and supplied to the blood and blood leukocytes and neutrophils in the animal.

The lutein is preferably provided in a dietary supplement for the animal which comprises, on a dry matter basis, from about 0.001 to about 2% by weight lutein. Where the companion animal is a dog, the supplement preferably comprises from about 0.01% to about 1% by weight lutein. Where the companion animal is a cat, the supplement preferably comprises from about 0.01% to about 1% by weight lutein.

Accordingly, it is a feature of the present invention to provide a pet food supplement and process for enhancing immune response and improving the overall health of companion animals such as dogs and cats by providing an effective amount of lutein in the diet of the animal. This, and other features and advantages of the present invention, will become apparent from the following detailed description, the accompanying drawings, and the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph of concentration of blood plasma lutein in dogs (nmol/L) versus time;

Fig. 2 is a graph of DTH response in dogs fed lutein daily for 6 weeks;

Fig. 3 is a graph of DTH response in dogs fed lutein daily for 12 weeks;

Fig. 4 is a graph of PHA-stimulated PBMC response in dogs fed lutein daily for 12 weeks;

Fig. 5 is a graph of Con A-stimulated PBMC response in dogs fed lutein daily for 12 weeks;

Fig. 6 is a graph of PWM-stimulated PBMC response in dogs fed lutein daily for 12 weeks;

5 Fig. 7 is a graph of the effect of dietary lutein on the percentages of CD4+ T-helper cells and CD8+ T-cytotoxic cells in dogs fed lutein daily for 12 weeks;

Fig. 8 is a graph of the effect of dietary lutein on the percentages of CD5+ cells and MHC II+ cells in dogs fed lutein daily for 12 weeks;

10 Fig. 9 is a graph of concentrations of plasma polyclonal IgG and IgM in dogs fed lutein daily for 17 weeks;

Fig. 10 is a graph of concentration of blood plasma lutein in cats ($\mu\text{mol/L}$) versus time;

Fig. 11 is a graph of Con A-stimulated PBMC response in cats fed lutein daily for 12 weeks;

15 Fig. 12 is a graph of PWM-stimulated PBMC response in cats fed lutein daily for 12 weeks;

Fig. 13 is a graph of DTH response in cats fed lutein daily for 6 weeks;

Fig. 14 is a graph of DTH response in cats fed lutein daily for 12 weeks;

Fig. 15 is a graph of the effect of dietary lutein on the percentages of CD3+ T cells and CD21+ B cells in cats fed lutein daily for 12 weeks;

20 Fig. 16 is a graph of the effect of dietary lutein on the percentages of CD4+ T-helper cells and CD8+ T-cytotoxic cells in cats fed lutein daily for 12 weeks; and

Fig. 17 is a graph of concentrations of plasma polyclonal IgG in dogs fed lutein daily for 12 weeks.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

25 The present invention uses a pet food composition which contains a source of lutein as a supplement in an amount between about 1 to 50 mg/day of lutein (from about 2 to about 315 mg lutein/kg diet). Such a diet provides sufficient lutein to be absorbed by the animal and supplied to

the blood and blood leukocytes and neutrophils in the animal. Both domestic dogs and cats are able to absorb dietary lutein. Furthermore, circulating lutein is significantly absorbed by both peripheral blood lymphocytes and neutrophils in such animals. Lutein is also distributed in the various subcellular organelles. Such lutein in the various organelles of leukocytes is believed to (1) protect these cells from oxygen free radical attack and/or (2) directly regulate nuclear events. Thus, feeding companion animals such as dogs and cats effective amounts of lutein provides lutein at important cellular sites in the body tissues of the animal which results in an up-regulation of immune function and improved health in such animals.

The pet food composition can be any suitable pet food formula which also provides adequate nutrition for the animal. For example, a typical canine diet for use in the present invention may contain about 20 to 40% crude protein, about 4 to 30% fat, and about 4 to 20% total dietary fiber. However, no specific ratios or percentages of these or other nutrients are required. The lutein may be blended with such pet food to provide the beneficial amounts needed.

In order that the invention may be more readily understood, reference is made to the following examples which are intended to illustrate the invention, but not limit the scope thereof.

Example 1 - Lutein Uptake in Dogs

Fifty six female Beagle dogs (17 to 18 months old; average body weight 11.4 ± 0.4 kg) were randomly assigned to be supplemented daily with 0, 5, 10 or 20 mg lutein for 17 weeks. The lutein contained 76.66% lutein and 5.23% zeaxanthin. The lutein supplement was resuspended in soybean oil to the appropriate concentration and 1 mL administered perorally at 0800 h daily. Food (200 g/dog/d) was offered immediately after the lutein supplementation. The basal diet shown in Table 1 below met or exceeded the requirements for all essential nutrients (NRC 1985).

Table 1

Component	Composition (g/kg)
Moisture	66
Protein	262
Ash	74
Fat	160
Calcium	14.8
Phosphorus	10.3
Gross Energy (kcal/kg)	4783

All dogs were housed in 2 x 2 m pens (2 dogs/pen) in a temperature (20 to 22°C) and light (14 h light) controlled facility. Body weight was recorded at weeks 0, 6, and 12.

Blood was collected by jugular venipuncture into heparinized evacuated tubes on weeks 0, 2, 4, 8 and 12 and aliquots used for HPLC analysis and for assessing immune responses.

Extraction and HPLC analysis

Plasma was extracted for analysis of lutein, zeaxanthin, retinol and α -tocopherol. Briefly, plasma protein was precipitated by adding an equal volume of ethanol containing 0.1 % butylated hydroxytoluene (BHT) (Aldrich Chemical Co., Milwaukee, WI). The mixture was extracted with 5 mL of a 1:1 mixture of petroleum ether:anhydrous diethyl ether.

The dried residue was resuspended in mobile phase consisting of a 47:47:6 (v:v:v) mixture of HPLC-grade acetonitrile: methanol: chloroform (Fisher Scientific, Fair Lawn, NJ). Lutein, zeaxanthin and α -tocopherol were quantitated by comparing the area under the curve whereas retinol was quantitated using peak height. The identity of the eluted compounds was confirmed

by comparing their absorption spectrum with that of pure standards. Because baseline separation of lutein and zeaxanthin was not accomplished, plasma concentrations were reported as lutein + zeaxanthin.

Delayed type hypersensitivity response

Skin induration response was assessed in all dogs on weeks 0, 6, and 12. Dogs were injected intradermally in the flank area with saline (8.5 g/L; control), an attenuated polyvalent vaccine containing canine distemper virus, canine adenovirus type-2, canine parainfluenza virus and parvovirus (Vanguard 5, Smithkline Beecham, West Chester, PA; specific antigen), and PHA (0.5 g/L; nonspecific antigen). The doses of vaccine and PHA used were previously determined to provide optimal skin response in Beagle dogs of similar age. The injection site was clipped and wiped with 70 % ethyl alcohol. The injection volume was 100 μ L. Skin induration was measured at 0, 24, 48 and 72 h post-injection with the aid of a pressure-sensitive digital micrometer (Mitsutoyo, Tokyo, Japan) and response was expressed as a percentage of skin thickness measured at 0 h.

Lymphocyte proliferation

Blood collected on weeks 0, 2, 4, 8 and 12 were used to assess mitogen-induced lymphocyte proliferation by peripheral blood mononuclear cells (PBMC). Whole blood culture was used in order to mimic in vivo conditions. Mitogens used were phytohemagglutinin (PHA), concanavalin A (Con A) and pokeweed mitogen (PWM). Whole blood was thoroughly mixed and then diluted 1: 12 with RPMI-1640 containing 25 mM of Hepes, penicillin (100 U/mL) and streptomycin (100 μ g/mL) (Sigma, St. Louis, MO). Preliminary studies using undiluted blood and blood diluted 1:2, 1:4, 1:8, 1:12 and 1:16 showed optimal PBMC proliferative response with a 1:12 dilution. Triplicate 150 μ L volumes were pipetted into 96-well round bottom plates and 50 μ L of the appropriate mitogens added. The final concentrations of the mitogens in culture were 2 and 10 μ g/mL for PHA, 1 and 5 μ g/mL for Con A and 0.5 and 2.5 μ g/mL for PWM. The two mitogen concentrations gave maximum (the higher mitogen concentration) and suboptimal (lower mitogen concentration) proliferative responses in preliminary studies using blood from

similar animals. The mixture was incubated for 72 h at 37°C in a humidified incubator under a 5 % CO₂ atmosphere. Four hours prior to the termination of the incubation period, 20 µL of [³H]-thymidine (1 [µCi/well]) were added. Cells were harvested onto fiberglass filters and radioactivity was counted by liquid scintillation. Proliferation response of PBMC was expressed as stimulation index (cpm of stimulated cultures/cpm of unstimulated cultures).

Lymphocyte subsets

Blood leukocytes were separated using Histopaque-1119 (Sigma, St. Louis, MO). Cells were washed three times with phosphate-buffered saline (PBS, pH 7.4) and contaminating erythrocytes were lysed in NH₄Cl (8.4 g/L). Lymphocyte subsets were determined by flow cytometry (FACScan, Becton Dickinson, San Jose, CA). Isolated mononuclear cells were resuspended to 1 x 10⁷ cells/mL in PBS supplemented with 2 % gamma globulin-free serum, 5 % goat serum and 0.2 g/L sodium azide. For immunofluorescence analysis, a total of 5 x 10⁵ cells were incubated for 30 minutes on ice with optimal concentrations of mouse anti-canine monoclonal antibody (mAb). The mAb used were specific for the following lymphocyte subsets: total T cells (anti-CD5), T-helper cells (anti-CD4), T-cytotoxic/suppressor cells (anti-CD8), lymphocytes expressing major histocompatibility complex (MHQ class II antigens (anti-MHC class II), and B cells (anti-CD21). Cells were then washed three times and incubated with a secondary antibody, fluorescein isothiocyanate (FITC)-conjugated goat F(ab')₂ anti-mouse IgG+IgM (H+L) (Caltag, Burlingame, CA), for 30 minutes on ice to visualize the bound mAb. Stained cells were fixed in 4 % paraformaldehyde in preparation for acquisition.

Appropriate negative controls were included to correct for background fluorescence. Data were expressed as the percentage of positive-staining cells corrected for cells stained nonspecifically with the secondary antibody.

NK Cell Cytotoxicity

Canine thyroid adenocarcinoma cells were used as target cells in assessing NK cell cytotoxic activity. This cell line was previously shown to be susceptible to killing by canine NK

cell. Target cells were cultured in a T75 flask with 20 mL minimum essential medium (MEM; Sigma Chem. Co., St. Louis, MO) supplemented with 10 % fetal calf serum (FCS), 100 U/mL of penicillin and 100 µg/mL of streptomycin. When confluent, target cells were trypsinized, washed 3 times and resuspended to 5×10^5 cells/mL in complete medium (RPMI- 1640 + 10 % FCS + 100 U/mL of penicillin + 100 µg/mL of streptomycin). Triplicate 100 µL aliquots of the target cells were pipetted into 96-well U-bottom plates (Costar, Cambridge, MA) and incubated for 8 hours to allow cell adherence. Lymphocytes (effector cells; 100 µL) isolated by percoll separation (as described above) were then added to the target cells to provide an effector:target cell (E:T) ratio of 10:1. After 10 hours of incubation at 37°C, 20 µl of a substrate containing 5 µg of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added. The mixture was incubated for 4 hours at 37°C after which the unmetabolized MTT was removed by aspiration. The formazan crystals were dissolved by adding 200 µL of 95 % ethanol. Optical density was measured at 570 nm using a microplate reader. The percentage of NK cell-specific lysis was calculated as follows:

$$\text{Specific cytotoxicity (\%)} = 100 \times \{1 - [(\text{OD of target cells and effector cells} - \text{OD of effector cells}) / (\text{OD of target cells})]\}$$

IL-2 production

Whole blood was diluted 1:2 with RPMI-1640 supplemented with Hepes and antibiotics (described earlier) and 400 µL of diluted blood were pipetted into 48-well plates (Costar, Cambridge, MA). Cells were stimulated with PHA (400 µL of a 5 µg/mL solution) for 48 hours at 37°C in a 5 % CO₂ atmosphere. The plates were centrifuged at 200 x g for 10 minutes and the supernatant was frozen at -80°C. The IL-2 content of the culture supernatant was determined in triplicate by ELISA (Intergen, Purchase, NY). The polyclonal anti-human IL-2 cross-reacted with canine IL-2 and recombinant human IL-2 was used as the standard.

Serum IgG and IgM

Serum collected on weeks 0, 2, 4, 8 and 12 were analyzed for IgG and IgM concentrations by single radial immunodiffusion (SRID). In addition, all dogs were vaccinated with the polyvalent vaccine (Vanguard 5, Smithkline Beacham, West Chester, PA) on week 13 and again on week 15 to study the possible anamnestic effect of dietary lutein. Blood was collected weekly from week 13 through week 17. Goat antiserum to canine IgG (10 %, whole molecule) or IgM (7.5 %, μ chain specific) (ICN, Aurora, OH) was mixed with melted agarose (10 g/L in PBS; Sigma Chem. Co., St. Louis, MO) and the mixture solidified in SRID plates. Duplicate 5 μ L volumes of serum or IgG (0, 2.88, 5.75, 11.5 and 23.0 mg/ml) or IgM (0, 0.25, 0.5, 1.0 and 2.0 mg/ml) standard were loaded into the wells. After incubating for 24 hours at room temperature in a humidified chamber, ring diameters were measured using a SRID reader (Transidyne General Corp., Ann Arbor, MI).

Lipid peroxidation (TBARS) assay

Plasma lipid peroxidation activity was determined by measuring malondialdehyde (MDA) production. The standard used was 1,1,3,3-tetramethoxypropane JMP) (Sigma Chem. Co., St. Louis, MO). Duplicate 500 μ L plasma samples were pipetted into 15 ml, glass tubes and 3 mL of 10 g/L phosphoric acid and 1 ml of 6 g/L TBA solution were added. The mixture was boiled in a water bath for 45 minutes. Tubes were allowed to cool and the TBA-MDA complex was extracted with 4 ml of n-butanol. The butanol layer was separated by centrifugation at 1,000 x g for 10 minutes and absorbance was measured on at 532 nm (Beckman, Fullerton, CA). The TBARS activity was expressed in nmole MDA/L plasma.

Statistics

Data were analyzed by split-plot ANOVA using the General Linear Model of SAS. The statistical model was $Y_{ijk} = \mu + \text{Diet}_i + \text{Dog}_j(\text{Diet}) + \text{Period}_k + \text{Diet}_i * \text{Period}_k + e_{ijk}$. Differences among treatment means were compared using orthogonal contrast and were considered statistically significant when $P < 0.05$.

RESULTS

Body weight

Dietary lutein did not significantly affect changes in body weight during the experimental period as shown below in Table 2. Body weight across all diets and periods averaged 11.4 ± 0.4 kg.

Table 2

Average body weight (kg) of dogs supplemented daily with 0, 5, 10 or 20 mg lutein¹

Week	Dietary lutein, mg/d			
	0	5	10	20
0	11.7 ± 0.3	11.2 ± 0.4	11.6 ± 0.5	11.2 ± 0.3
6	11.0 ± 0.3	11.0 ± 0.3	11.5 ± 0.3	10.9 ± 0.3
12	12.1 ± 0.4	11.7 ± 0.4	11.8 ± 0.4	11.6 ± 0.3

¹Values are means \pm SEM (n = 14/diet/period). There was no significant treatment difference in body weight within a sampling period as analyzed by repeated measures ANOVA.

Plasma

Plasma concentrations of lutein + zeaxanthin in lutein-supplemented dogs increased rapidly after 2 weeks of feeding (Figure 1). Plasma concentrations continued to increase thereafter, although more gradually, in dogs fed 10 and 20 mg lutein. In contrast, plasma lutein + zeaxanthin was not detectable in unsupplemented dogs. Concentrations of plasma lutein + zeaxanthin on weeks 2 through 12 was significantly higher ($P < 0.05$) in dogs fed lutein than in unsupplemented animals. Lutein supplementation did not influence concentrations of plasma retinol and α -tocopherol. Concentrations of these vitamins across all treatments and all periods averaged 3.63 ± 0.14 and 37 ± 2 $\mu\text{mol/L}$, respectively.

Delayed-type hypersensitivity response

During all periods studied, DTH response to saline was low (3 to 10 % increase in skin thickness) and did not differ significantly among treatment groups. Prior to lutein feeding (week 0), DTH responses to PHA and vaccine were similar across all dietary groups. Irrespective of treatment period, maximal DTH response to PHA was observed around 24 h post-injection whereas maximal response to vaccine occurred between 48 and 72 h. Also, skin thickness response to PHA was approximately two times higher than to vaccine.

On week 6, there was a dose-related DTH response to PHA at 24 h post-injection as shown in Fig. 2. The DTH response decreased by 48 and 72 h and no significant treatment difference was observed during these times. The DTH response to vaccine was dose-related at 48 and 72 h post-injection and was not significant at 24 h.

On week 12, there was a general dose-dependent increase in DTH response to PHA at 24, 48 and 72 h as shown in Fig. 3; however, the response was significantly higher for dogs fed 20 mg lutein compared to unsupplemented dogs. In contrast to week 6, there was no significant dietary effect on DTH response to vaccine.

Mitogen-induced PBMC proliferation

Dietary lutein did not significantly influence spontaneous proliferation by unstimulated PBMC. There was no significant effect of dietary lutein on PHA-stimulated PBMC response on weeks 0 and 4 as shown in Fig. 4. However, proliferative response was enhanced ($P < 0.01$) on weeks 8 (10 $\mu\text{g/mL}$ PHA) and 12 (2 and 10 $\mu\text{g/mL}$ PHA) in dogs fed 20 mg lutein compared to unsupplemented dogs. Dogs fed 5 and 10 mg lutein also had higher PBMC proliferation on week 8 in response to 10 $\mu\text{g/mL}$ PHA.

The effects of dietary lutein on Con A-stimulated PBMC proliferative response (see Figure 5) were generally similar to those observed with PHA-induced proliferation. On weeks 8 and 12, dogs fed 20 mg lutein had higher PBMC proliferation in response to both concentrations of Con A. Dogs fed 10 mg lutein also showed higher PBMC proliferation on weeks 8 and 12 in response

to 5 µg/mL Con A. Generally, PBMC proliferation was higher with 5 µg/mL than with 1 µg/mL Con A.

Proliferation of PBMC in response to PWM (Figure 6) was generally similar to those observed with PHA and Con A. Dogs fed 20 mg lutein had significantly higher PBMC proliferation on week 8 and 12 in response to both concentrations of PWM as compared to unsupplemented controls. Those fed 10 mg lutein also had higher proliferative response on week 8. Again, no significant treatment difference was observed at weeks 0 and 4.

Natural killer cell cytotoxic activity

Dietary lutein supplementation did not significantly influence NK cell cytotoxic activity. Specific lysis of target cells by PBMC averaged 49.1 ± 1.1 % across all treatments and sampling periods.

Lymphocyte subpopulations

The effects of dietary lutein on the percentages of CD5+, CD4+, CD8+, CD21+ (B cells) and MHC class II lymphocyte subpopulations are illustrated in Figures 7 and 8. Prior to dietary lutein supplementation (week 0), there were no significant differences in the percentages of any of the lymphocyte markers. On week 12, % CD4+ cells was higher in dogs fed 5 and 10 mg lutein whereas the CD8+ population was not influenced by the diet (Figure 7). On the other hand, dogs fed 20 mg lutein had significantly higher % CD8+ T cytotoxic cells on week 8 compared to control. The ratio of CD4:CD8 was similar among treatments on weeks 0, 4 and 8 but tended to be higher ($P < 0.08$) in dogs fed 10 mg (2.50 ± 0.16) compared to control (2.10 ± 0.16).

On weeks 4 and 8, dogs fed lutein generally had higher percentages of CD5+ cells than unsupplemented controls and was statistically significant with dogs fed 5 and 20 mg lutein (Figure 8). Dogs fed 20 mg lutein also had elevated % MHC class II cell populations on week 8 and 12 compared to unsupplemented dogs (Figure 8). Dogs fed lower amount of lutein had MHC class II populations similar to control.

In contrast to other lymphocyte subpopulations, dietary lutein did not significantly influence the CD21+ B cell population.

Interleukin-2 production

The production of IL-2 by PHA-stimulated PBMC in whole blood cultures did not differ significantly among dietary treatments throughout the experimental period. Concentrations of IL-2 in culture medium averaged 15.7 ± 0.4 ng/mL throughout the study.

Immunoglobulin production

Plasma IgG concentrations tended to increase ($P > 0.05$) throughout the 17-week sampling period as illustrated in Fig. 9. Concentrations were similar among dietary treatments during the first 12 weeks of dietary supplementation. However, after revaccination on week 15, plasma IgG was higher ($P < 0.05$) on week 16 in dogs fed 5 mg lutein ($P < 0.05$) and on week 17 in dogs fed 20 mg lutein whereas the concentration of plasma IgM was not changed (Fig. 9).

Lipid peroxidation

Lutein supplementation did not significantly affect plasma TBARS activity which averaged 95.8 ± 0.1 nmol MDA/L across all treatments and periods.

Discussion

The results show that dietary lutein significantly enhances cell-mediated immune response in the dog. Lutein supplementation stimulated the proliferative response of PBMC to PHA, Con A and PWM. There was a marked increase in PBMC proliferation in response to PHA and Con A at week 12 in dogs fed 20 mg lutein.

The data shows that enhanced mitogenesis by dietary lutein is likely attributed to increased population of lymphocytes. Dogs supplemented with lutein had higher populations of CD5+ and CD4+ cells. Dietary lutein may specifically act on T lymphocytes because no changes in B cell population were observed with lutein supplementation.

The data also showed that lutein supplementation significantly increased PWM-induced PBMC proliferation at weeks 8 and 12.

Dietary lutein also significantly increased the DTH response to vaccine, which is indicative of a specific immune response. While not wishing to be bound by any particular theory, this heightened DTH response may be explained through an increased population of MHC class II cells responsible for antigen processing and presentation. Lutein supplementation significantly increased the number of cells stained positive for MHC class II molecules compared to unsupplemented dogs.

Lutein did not significantly affect polyclonal antibody (IgG and IgM) production ex vivo in the canine during the first 12 weeks of supplementation. However, upon reexposure to the antigen, plasma IgG concentrations increased in lutein fed dogs, suggesting an anamnestic effect of dietary lutein in increasing the memory B cells' ability to secrete IgG.

In summary, dietary lutein enhanced canine T-helper cell population and the expression of MHC class II molecules, resulting in increased mitogen-induced canine PBMC proliferation and DTH response. Also, lutein is believed to increase Ig production.

Example 2 - Lutein Uptake in Cats.

Fifty-six female Tabby cats (10 months old) were randomly assigned to be fed 0, 1, 5, or 10 mg lutein daily for 12 weeks. The lutein contained 76.66% lutein and 5.23% zeaxanthin and was incorporated into the basal diet (see Table 3) to a final concentration of 250 mg lutein/kg of diet.

Table 3

Component	Composition (g/kg)
Moisture	72
Protein	310
Ash	52
Fat	217
Crude fiber	14
Calcium	11.5
Phosphorus	8.3
Gross Energy (kcal/kg)	5412

Prior to being fed to the cats, the lutein-containing diet was mixed with additional basal diet to achieve the desired lutein concentration. The final diets were mixed weekly and stored at -20°C in sealed containers under nitrogen gas. Prepared food analyzed periodically showed no significant destruction of lutein. Food and water were available ad libitum. Cats were housed (7 cats/pen; 1.5 x 5.0 m) in a temperature (20 to 22°C) and light (14 h light) controlled facility.

Blood was collected by jugular venipuncture into heparinized evacuated tubes on weeks 0, 2, 4, 8 and 12 and aliquots used for HPLC analysis and for assessing immune responses.

Extraction of plasma for HPLC

Plasma lutein, retinol and α -tocopherol were analyzed by reverse phase HPLC. Briefly, plasma protein was precipitated with an equal volume of ethanol containing 0.1% butylated hydroxytoluene (BHT) (Aldrich Chemical Co., Milwaukee, WI). The mixture was extracted with 5 ml of a 1:1 mixture of petroleum ether:anhydrous diethyl ether and the dried residue resuspended in mobile phase. The mobile phase was a mixture of acetonitrile, methanol and chloroform (47:47:6, v/v/v). The internal standard used was retinyl acetate (Sigma Chem. Co.,

St. Louis, MO). Samples were eluted on a 5 μ m C18 reverse phase column (3.9 x 150 mm; Resolve, Millipore Corp., Milford MA) with a flow rate of 1.0 ml/min. The identity of the eluted compounds was verified by comparing their absorption spectra with those of standard compounds.

5 Delayed type hypersensitivity (DTH)

10 The DTH response was evaluated on week 0, 6, and 12 after the initiation of lutein feeding. Cats were mildly sedated with an i.m. injection of ketamine hydrochloride (5 mg/kg; Fort Dodge, IA) and acepromazine (0.1 mg/kg; Vedco, St. Joseph, MO). The hair on the flank was clipped and the area wiped with 70% ethyl alcohol. All cats were injected i.d. with 100 μ l of saline (8.5 g/L; control), concanavalin A (Con A; 0.5 g/L) to measure nonspecific immunity, and with an attenuated polyvalent vaccine (Felocell, Pfizer, NY, NY) containing feline herpesvirus-1, feline calicivirus, feline parvovirus and Chlamydia psittaci to measure specific immunity. The DTH response was assessed by measuring skin induration at 24, 48 and 72 h after injection with the aid of a digital micrometer (Mitsutoyo, Tokyo, Japan). The response was expressed as a percentage of skin thickness measured at the same injection site at 0 h.

15 Peripheral blood mononuclear cell proliferation

20 Whole blood was used to analyze the mitogenic proliferative responsiveness of peripheral blood mononuclear cells (PBMC) to phytohemagglutinin (PHA), Con A and pokeweed mitogen (PWM) in order to mimic in vivo conditions. Heparinized whole blood was diluted 1:12 with RPMI-1640 containing 25 mM of Hepes, penicillin (100 U/mL) and streptomycin (100 μ g/mL) (Sigma, St. Louis, MO) (hereafter termed complete medium). Preliminary studies using undiluted blood and blood diluted 1:2, 1:4, 1:8, 1:12 and 1:16 showed optimal repeatability and response to mitogens with the 1:12 dilution. The mitogens were used at the following final concentrations previously determined to provide both maximal (the higher mitogen concentration) and suboptimal (the lower mitogen concentration) proliferation: PHA (1.25 and 0.25 μ g/mL), Con A (2.5 and 0.5 μ g/mL) or PWM (0.125 and 0.025 μ g/mL). Tritiated thymidine uptake was

measured by liquid scintillation and PBMC proliferation response was expressed as cpm of stimulated cultures corrected for cpm of unstimulated cultures.

Lymphocyte subpopulations

Blood leukocytes were separated on Histopaque-1119 (Sigma, St. Louis, MO) and cells washed three times with phosphate-buffered saline (PBS, pH 7.4). Contaminating RBC were lysed with NH_4Cl (8.4 g/L) and cell viability determined by trypan blue exclusion. Lymphocyte subsets were determined by FACScan flow cytometry (Becton Dickinson, San Jose, CA) immediately after cell preparation. Isolated PBMC were resuspended to 1×10^7 cells/mL phosphate buffered saline (PBS) supplemented with 2% gamma globulin-free serum, 5% goat serum and 0.2 g/L sodium azide (Baker, Phillipsburg, NJ). For immunofluorescence analysis, 5×10^5 cells were incubated for 30 minutes on ice with a previously determined optimal concentration of mouse anti-cat primary monoclonal antibody. The antibodies were specific for the following lymphocyte subsets: total T cells (anti-CD3), T-helper cells (anti-CD4), T cytotoxic/suppressor cells (anti-CD8), lymphocytes expressing major histocompatibility complex (MHC) class II antigens (anti-MHC class II), and B cells (anti-CD21). Cells were then washed three times and incubated with a secondary antibody, fluorescein isothiocyanate (FITC)-conjugated goat F(ab')₂ anti-mouse IgG (H+L) (Caltag, Burlingame, CA) for 30 minutes on ice to visualize the bound antibody. Stained cells were fixed in 4% paraformaldehyde in preparation for acquisition. Appropriate negative controls were included to correct the level of background fluorescence. Fluorescence analysis was performed on lymphocytes gated by forward and side scatter. Data were expressed as a percentage of positive-staining cells corrected for cells stained nonspecifically with the secondary antibody.

NK cytotoxicity assay

The Crandell feline kidney fibroblast was used as the target cell. Target cells were resuspended to 2×10^5 cells/mL and triplicate 100 μL aliquots were pipetted into a 96-well U-bottom plate (Costar, Cambridge, MA) and cells allowed to adhere. Isolated PBMC (effector

cells) were then added to the target cells to achieve effector:target cell (E:T) ratios of 25:1, 12.5:1 and 6.25:1. The cell mixture was incubated for 8 hours after which 100 μ L Rose Bengal (2.5 g/L in PBS; Sigma, St. Louis, MO) were added and incubated at room temperature for 5 minutes. Optical density was measured at 550 nm using an ELISA plate reader. The percentage of NK-specific lysis was calculated as follows:

$$\text{Specific cytotoxicity (\%)} = 100 \times \{1 - [(\text{OD of target cells and effector cells} - \text{OD of effector cells}) / (\text{OD of target cells})]\}$$

IL-2 production

Whole blood was diluted 1:2 in RPMI-1640 complete medium and cultured for 48 hours in the presence of 5 μ g/mL Con A. The conditioned medium was removed and frozen at -80°C. The IL-2 concentrations were determined in duplicate by ELISA using a human IL-2 kit (Intergen, Purchase, NY). The human anti-IL-2 was previously determined to cross-react with feline IL-2.

Serum IgG

Serum IgG concentration was determined by single radial immunodiffusion (SRID). Goat antiserum to cat IgG (15%, whole molecule) (Sigma, St. Louis, MO) was incorporated into agarose (10 g/L in PBS; Sigma, St. Louis, MO). The loading volume for the test serum and standard was 5 μ L and the plates were incubated for 24 hours in a humidified chamber. Ring diameters were measured using a SRID reader (Transidyne General Corp., Ann Arbor, MI).

Lipid peroxidation (TBARS)

Lipid peroxidation was assessed by the TBARS (thiobarbituric acid-reactive substances) assay on plasma collected on weeks 0, 2, 4, 8 and 12. Duplicate 500 μ L of cat plasma was boiled for 45 minutes with 3 mL of phosphoric acid (10 g/L) and 1 mL of TBA (6 g/L). After cooling, the TBA-MDA (malondialdehyde) complex was extracted with 4 mL of n-butanol. The butanol layer was separated by centrifugation (1,000 x g for 10 minutes) and absorbance read (Beckman,

Fullerton, CA) at 532 nm. The absorbance unit was converted to nmoles MDA from a standard curve generated with a 1,1,3,3,-tetramethoxypropane (TMP) (Sigma, St. Louis, MO).

Statistics

Data were analyzed by split-plot ANOVA using the General Linear Model of SAS (Statistical Analysis System). The statistical model was $Y_{ijk} = \mu + \text{Treatment}_i + \text{Cat}_j(\text{Treatment}_i)$ (subplot error term to be used to test the effects of treatment) + $\text{Sampling period}_k + \text{Treatment}_i * \text{Period}_k + e_{ijk}$. Differences between treatment means within a sampling period were compared using orthogonal contrast. Differences with $P < 0.05$ were considered as statistically significant.

RESULTS

Body weight and food intake

Dietary lutein did not significantly affect changes in body weight during the experimental period (data not shown). Body weight across all diets and periods averaged 1.41 ± 0.04 kg. Average daily food intake was 83.2 g across the study period and was not significantly different among treatments.

Plasma lutein

Prior to lutein supplementation, the baseline plasma lutein concentration averaged 0.036 ± 0.005 $\mu\text{mol/L}$ in all cats. Lutein concentrations in unsupplemented cats remained at this concentration throughout the study period. Plasma lutein increased in a dose-dependent manner between week 2 and 12 as shown in Fig. 10. Lutein concentrations in lutein-fed cats increased rapidly on week 2 and concentrations continued to increase, albeit more gradually, through week 12 in cats fed 5 or 10 mg lutein. Lutein supplementation did not influence the concentration of plasma retinol and α -tocopherol which averaged 0.56 ± 0.03 and 14.9 ± 0.9 $\mu\text{mol/L}$, respectively.

Mitogen-induced PBMC proliferation

Dietary lutein did not significantly influence spontaneous proliferation by unstimulated PBMC and averaged $1,744 \pm 147$ cpm throughout the study. Cats fed 10 mg lutein showed significantly higher PBMC proliferative response to Con A ($2.5 \mu\text{g/mL}$) at week 4 but treatment differences were not observed on week 8 and 12 (see Fig. 11). No significant treatment difference was observed with a suboptimal dose ($0.5 \mu\text{g/mL}$) of Con A. There were no significant dietary effects on PHA-induced PBMC proliferation throughout the study. Tritiated thymidine uptake with 1.25 and $0.25 \mu\text{g/mL}$ PHA averaged $6,464 \pm 504$ and $1,934 \pm 147$ cpm, respectively. Of the 3 mitogens used, PWM produced the highest proliferation (Figure 12). Lutein supplemented generally increased PBMC proliferation on week 4; differences were significant when cultures were stimulated with $0.125 \mu\text{g/mL}$ (1 and 10 mg lutein) and $0.025 \mu\text{g/mL}$ (1 mg lutein) of PWM.

Delayed-type hypersensitivity (DTH)

Prior to lutein supplementation, no significant differences were observed in DTH response among dietary treatments (data not shown). The DTH response to saline was low (averaged $4.3 \pm 0.6\%$) and not significantly different among treatments during all periods studied. On week 6, no significant dietary effect on DTH response to Con A was observed (Fig. 13). However, by week 6 of lutein feeding, there was a significant dose-related DTH response to vaccine when measured at 72 h post-injection; response was significantly higher with cats fed 5 or 10 mg lutein. By week 12, no significant treatment difference was observed with both Con A and vaccine (Fig. 14); however, the same general trend in a dose-related DTH response persisted with vaccine on week 12 at 72 h postinjection as was observed on week 6.

In general, peak DTH response to Con A was observed around 24 h post-injection whereas maximal response to vaccine occurred between 48 and 72 h.

Natural killer (NK) cell activity

Cytotoxicity activity of NK cells at effector:target cell (E:T) ratios of 6.25:1, 12.5:1 and 25:1 are illustrated in Table 4.

Table 4

Natural killer (NK) cell activity (% specific lysis) of isolated PBMC in cats fed daily with 0, 1, 5, or 10 mg lutein¹

		Dietary lutein (mg/d)			
Week		0	1	5	10
<u>Effector: Target ratio of 6.25:1</u>					
10	0	18.4 ± 6.1 ^a	19.8 ± 5.5 ^a	17.1 ± 5.8 ^a	22.8 ± 6.5 ^a
	4	42.8 ± 4.8 ^{ab}	46.6 ± 4.6 ^a	41.2 ± 5.0 ^{ab}	33.2 ± 4.8 ^a
	8	24.9 ± 5.3 ^b	28.0 ± 4.8 ^{ab}	34.3 ± 5.0 ^{ab}	41.1 ± 5.5 ^a
	12	26.2 ± 5.0 ^b	45.8 ± 5.5 ^a	37.4 ± 5.8 ^{ab}	39.7 ± 6.1 ^{ab}
<u>Effector: Target ratio of 12.5:1</u>					
15	0	28.5 ± 5.8 ^a	30.0 ± 7.0 ^a	20.8 ± 7.0 ^a	20.7 ± 8.2 ^a
	4	44.4 ± 5.3 ^a	44.1 ± 4.9 ^a	37.5 ± 5.1 ^a	33.7 ± 5.1 ^a
	8	33.3 ± 6.4 ^{ab}	27.4 ± 6.5 ^b	44.4 ± 6.2 ^{ab}	48.2 ± 6.5 ^a
	12	33.8 ± 6.4 ^a	40.5 ± 6.1 ^a	35.9 ± 5.8 ^a	38.2 ± 7.0 ^a
<u>Effector: Target ratio of 25:1</u>					
20	0	27.6 ± 6.1 ^{ab}	21.2 ± 6.2 ^{ab}	17.2 ± 6.3 ^b	38.8 ± 8.3 ^a
	4	39.5 ± 5.2 ^a	36.2 ± 4.4 ^a	45.0 ± 4.9 ^a	33.9 ± 4.6 ^a
	8	32.2 ± 6.7 ^c	44.9 ± 8.0 ^{ab}	32.6 ± 5.3 ^{bc}	47.8 ± 5.5 ^a
	12	34.0 ± 10.2 ^a	35.6 ± 6.2 ^a	26.9 ± 6.3 ^a	29.2 ± 9.5 ^a

¹Values are presented as means ± SEM (n=14/diet/period). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly, P < 0.05

No significant treatment difference in cytotoxicity was observed on week 0 prior to lutein supplementation. However, on week 8, NK cell cytotoxic activity was higher in cats fed 10 mg lutein; differences were significant with E:T ratios of 6.25:1 and 25:1. Also, cats fed 1 mg lutein also showed significantly higher cytotoxicity on week 12 (E:T of 6.25:1) and 8 (E:T of 25:1). No

significant treatment differences were observed with E:T ratio of 12.5:1 even though the same general trend was evident.

Lymphocyte subpopulations

Dietary lutein did not influence significantly the total number of T cells (CD3) (Figure 15) However, on week 12 of supplementation, the percentage of CD21 + B cells was significantly elevated in cats fed 10 mg lutein. Changes in the CD4+ T helper cell population (Figure 16) were similar to that of the CD21+ cells. In contrast, the percentage of CD8+ T cytotoxic cells (Figure 10), the ratio of CD4:CD8, and the percentage of MHC class II+ cells were not influenced significantly by dietary lutein in any of the time periods studied.

Interleukin-2 production

There were no significant differences in IL-2 production throughout the experimental period. The average concentration of IL-2 in Con A-stimulated cultures throughout the study was 15.1 ± 0.79 ng/mL.

Antibody production

Plasma IgG concentration was not significantly different at the commencement of the study and averaged 15.85 ± 0.62 mg/mL (Figure 17). However, by week 8 of lutein feeding, cats fed 1 or 10 mg lutein had significantly higher concentrations of plasma IgG. This trend persisted through week 12 where plasma IgG in cats fed 10 mg lutein remained significantly higher than unsupplemented animals.

Lipid peroxidation

Dietary lutein did not significantly influence plasma TBARS activity and concentrations averaged 20.3 ± 0.2 nmol MDA/L across all diet groups and periods.

Discussion

The results showed that lutein modulates immune response in the domestic cat. Cats absorb lutein into the blood and the lutein is subsequently taken up by circulating leukocytes. The results showed that the absorption of lutein is dose- and time-dependent and does not significantly alter plasma concentrations of retinol and α -tocopherol.

Dietary lutein stimulated the proliferative response of PBMC to Con A and PWM. The enhanced lymphocyte proliferation by dietary lutein is most likely mediated via the alteration of cell surface marker expression on lymphocytes.

Dietary lutein also significantly increased the B and T-helper cell populations. NK cell cytotoxic activity was also enhanced by dietary lutein. Lutein is believed to upregulate NK cell activity through the activation of Th cells or its direct action on NK cells.

Dietary lutein significantly increased DTH response to vaccine in a dose-related manner at week 6. However, there was no significant boosting effect with repeated inoculation of the antigens. Even though no marked changes in total T cell population were observed, lutein supplementation significantly increased the CD4⁺ T helper cell population but not the CD8⁺ T cytotoxic cells. This increase in T helper cells may explain the enhanced DTH response observed in lutein-supplemented cats.

Cats fed lutein also showed significantly higher serum IgG concentrations. The observed enhancing effect of lutein on antibody production is believed to be mediated through the action of the T helper cells.

In summary, the data indicates that dietary lutein is an important immunomodulating micronutrient in the domestic cat.

While certain representative embodiments and details have been shown for purposes of illustrating the invention, it will be apparent to those skilled in the art that various changes in the methods and apparatus disclosed herein may be made without departing from the scope of the invention, which is defined in the appended claims.

What is claimed is:

CLAIMS

1. A process for enhancing immune response and improving the overall health of a companion animal comprising the step of feeding said animal a diet containing an effective amount of lutein for a time sufficient for said lutein to be absorbed by said animal.

2. A process claimed in claim 1 in which said diet includes from about 1 to about 50 mg/day of lutein.

3. A process as claimed in claim 1 in which said diet includes from about 2 to about 315 mg lutein per kg of diet.

4. A process as claimed in claim 1 wherein said companion animal is a dog.

5. A process as claimed in claim 4 in which said diet includes from about 5 to about 20 mg/day of lutein.

6. A process as claimed in claim 1 wherein said companion animal is a cat.

7. A process as claimed in claim 6 in which said diet includes from about 5 to about 10 mg/day of lutein.

8. A process as claimed in claim 1 in which said diet comprises about 20 to 40% crude protein, about 4 to 30% fat, and about 4 to 20% total dietary fiber.

9. A process for increasing the lutein concentration in the circulating blood of a companion animal comprising the step of feeding said animal a diet containing an effective amount of lutein for a time sufficient for said lutein to be absorbed into the bloodstream of said animal.

10. A process for increasing IgG concentrations in a companion animal comprising the step of feeding said animal a diet containing an effective amount of lutein for a time sufficient for said lutein to be absorbed into the bloodstream of said animal.

11. A process for increasing lymphocyte cells in a companion animal comprising the step of feeding said animal a diet containing an effective amount of lutein for a time sufficient for said lutein to be absorbed into the bloodstream of said animal.

12. A supplement for enhancing immune response and improving the overall health of a companion animal comprising, on a dry matter basis, from about 0.001 to about 2% by weight lutein.

13. The supplement as claimed in claim 12 wherein said companion animal is a dog.

14. The supplement as claimed in claim 13 comprising from about 0.01% to about 1% by weight lutein.

15. The supplement as claimed in claim 12 wherein said companion animal is a cat.

16. The supplement as claimed in claim 15 comprising from about 0.01% to about 1% by weight lutein.

ABSTRACT

A food supplement and process for feeding a companion animal such as a dog or cat a diet containing an effective amount of lutein to enhance immune response and improve the overall health of the animal is provided. Preferably, the diet includes from about 1 to about 50 mg/day of lutein (from about 2 to about 315 mg lutein/kg diet). Such a diet provides sufficient lutein to be absorbed by the animal and supplied by the blood and blood leukocytes and neutrophils in the animal.

5

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2




Figure 1 Concentrations of plasma lutein + zeaxanthin in dogs fed diets containing 0, 5, 10 or 20 mg lutein for 12 wk. Values are means \pm SEM ($n = 14$). Lutein + zeaxanthin was not detectable in unsupplemented dogs. Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$. nd = non-detectable.




Figure 2 Delayed-type hypersensitivity response (expressed as a percentage of skin thickness measured at 0 h) in dogs fed 0, 5, 10, or 20 mg lutein daily for 6 wk. Dogs were challenged with PHA (top panel) and a polyvalent vaccine (bottom panel) and skin induration was measured at 0, 24, 48 and 72 h post-injection. Values are means \pm SEM ($n = 14$ dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$.




Figure 3 Delayed-type hypersensitivity response (expressed as a percentage of skin thickness measured at 0 h) in dogs fed 0, 5, 10, or 20 mg lutein daily for 12 wk. Dogs were challenged with PHA (top panel) and a polyvalent vaccine (bottom panel) and skin induration was measured at 0, 24, 48 and 72 h post-injection. Values are means \pm SEM ($n = 14$ dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$.




Figure 4 Incorporation of [^3H]-thymidine by PHA-induced (10 or 2 µg/mL) PBMC in dogs fed 0, 5, 10, or 20 mg lutein daily. Values are means \pm SEM ($n = 14$ dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly, $P < 0.05$.

Concanavalin A




Figure 5 Incorporation of [^3H]-thymidine by Con A-induced (5 or 1 µg/mL) PBMC in dogs fed 0, 5, 10, or 20 mg lutein daily. Values are means \pm SEM ($n = 14$ dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$.

Pokeweed Mitogen




Figure 6 Incorporation of [^3H]-thymidine by PWM-induced (2.5 or 0.5 µg/mL) PBMC in dogs fed 0, 5, 10, or 20 mg lutein daily. Values are means \pm SEM ($n = 14$ dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly, $P < 0.05$.




Figure 7 Percentages (calculated by expressing the number of cells that stained positive for surface marker as a percentage of total number of lymphocytes) of CD4+ T-helper (above) and T cytotoxic/suppressor CD8+ (bottom) lymphocyte subpopulations in dogs fed 0, 5, 10, or 20 mg lutein daily for 12 wk. Values are means \pm SEM ($n = 14$ dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$.




Figure 8 Percentages (calculated by expressing the number of cells that stained positive for the cell surface marker as a percentage of total number of lymphocytes) of CD5 positive (above) and MHC class II positive (bottom) lymphocytes in dogs fed 0, 5, 10, or 20 mg lutein daily for 12 wk. Values are means \pm SEM ($n = 14$ dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$.




Figure 9 Concentrations of plasma polyclonal IgG (above) and IgM (bottom) in dogs fed 0, 5, 10, or 20 mg lutein daily for 17 wk. All dogs were vaccinated with a polyclonal vaccine on wk 13 and 15. Values are means \pm SEM ($n = 14$ dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$.




Figure 10 Concentrations of plasma lutein from cats fed diets containing 0, 1, 5 or 10 mg lutein for 12 wk. Values are means \pm SEM ($n = 14$ cats/diet). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly, $P < 0.05$.




Figure // Incorporation of [³H]-thymidine by Con A-induced (2.5 or 0.5 µg/mL) PBMC from cats fed 0, 1, 5, or 10 mg lutein daily. Values are means ± SEM (n = 14 cats diet). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly, *P* < 0.05.




Figure 12 Incorporation of [³H]-thymidine by PWM-induced (0.125 or 0.025 µg/mL) PBMC from cats fed 0, 1, 5, or 10 mg lutein daily. Values are means ± SEM (n = 14 cats/diet). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly, *P* < 0.05.

Week 6




Figure 13 Delayed-type hypersensitivity response (expressed as a percentage of skin thickness measured at 0 h) in cats fed 0, 1, 5, or 10 mg lutein daily for 6 wk. Values are means \pm SEM ($n = 14$ cats/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$. Cats were challenged with Con A (top panel) and a polyvalent vaccine (bottom panel) and skin induration measured at 0, 24, 48 and 72 h post-injection.




Figure 4 Delayed-type hypersensitivity response (expressed as a percentage of skin thickness measured at 0 h) in cats fed 0, 1, 5, or 10 mg lutein daily for 12 wk. Values are means \pm SEM ($n = 14$ cats/diet). Data were analyzed by repeated measures ANOVA. There was no significant difference among treatments at all sampling periods. Cats were challenged with Con A (top panel) and a polyvalent vaccine (bottom panel) and skin induration measured at 0, 24, 48 and 72 h post-injection.




Figure 15 Percentages (calculated by expressing the number of cells that stained positive for the cell surface marker as a percentage of total number of lymphocytes) of CD3 positive (Total T cells, above) and CD21 positive (B cells, bottom) lymphocytes in cats fed 0, 1, 5, or 10 mg lutein daily for 12 wk. Values are means \pm SEM ($n = 14$ cats/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$.




Figure 10 Percentages (calculated by expressing the number of cells that stained positive for surface marker as a percentage of total number of lymphocytes) of CD4+ T-helper (above) and CD8+ T-cytotoxic/suppressor (bottom) lymphocyte subpopulations in cats fed 0, 1, 5, or 10 mg lutein daily for 12 wk. Values are means \pm SEM ($n = 14$ cats/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$.




Figure 17 Concentrations of plasma polyclonal IgG in cats fed 0, 1, 5, or 10 mg lutein daily for 12 wk. Values are means \pm SEM ($n = 14$ cats/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly, $P < 0.05$.

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the invention entitled:

LUTEIN-CONTAINING SUPPLEMENT AND PROCESSOR FOR ENHANCING IMMUNE RESPONSE IN ANIMALS (Docket IAM 467 PA), described and claimed

XX in the attached specification;
 _____ in the specification filed _____
 as U.S. Application Serial No. _____, and as amended _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims as filed and as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under 35 USC § 119(e) of any United States provisional application(s) listed below:

Application Number	Filing Date
<u>60/081,968</u>	<u>April 16, 1998</u>

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Richard A. Killworth	Reg. No. 26,397
James F. Gottman	Reg. No. 27,262
Timothy W. Hagan	Reg. No. 29,001
Richard C. Stevens	Reg. No. 28,046
Robert L. Showalter	Reg. No. 33,579
James E. Beyer	Reg. No. 39,564
Susan M. Luna	Reg. No. 38,769
Carolyn M. Sloane	Reg. No. 44,339
Daniel C. Stelter	Reg. No. 40,830

Address all telephone calls to (937) 223-2050. Address all correspondence to: KILLWORTH, GOTTMAN, HAGAN & SCHAEFF, L.L.P., One Dayton Centre, One South Main Street, Suite 500, Dayton, Ohio 45402-2023.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole or first Inventor: Michael G. Hayek

Inventor's signature Michael G. Hayek

Date: April 8, 1999

Residence: 926 Tammy Circle
Dayton, Ohio 45415-2136

Citizenship: U.S.A.

Post Office Address: c/o The Iams Company
7250 Poe Avenue
Dayton, Ohio 45414